Alexandria Real Estate Equities owns lab and office buildings used by life science companies, but empty space is rising and the company just cut its payout to save cash. The flip side is that the shares trade at a steep discount to what its properties and projects could be worth if leasing and asset sales start to stabilize.Read more
Alexandria builds and runs lab campuses in major science hubs, and it could benefit if research spending keeps rising and more drug companies sign long leases for specialized space. But higher borrowing costs, more new lab buildings coming online, and slower tenant decisions could make it harder to keep buildings full and rents moving up.Read more
Key Takeaways Premium assets in major innovation clusters secure long-term leases with top tenants, supporting stable cash flows and above-market rent growth. Rising demand for specialized lab space and high entry barriers strengthen Alexandria's competitive position and earnings potential.Read more
Key Takeaways Rising costs, regulatory pressures, and shifts in workplace demand are squeezing margins and threatening predictability of earnings and occupancy rates. Heavy dependence on key biotech hubs and evolving funding trends increases revenue volatility and prolongs vacancy risks.Read more
Alexandria Real Estate Equities, Inc., an S&P 500 company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator and developer of collaborative Megacampus ecosystems in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle and New York City. Alexandria Real Estate Equities, Inc. is based in Pasadena, California and is established in January 05, 1994, and incorporated in Maryland.
